Podcasts about perelman center

Send us a textGuest: Nora SchellActor / Singer / SongwriterIn this interview episode, we speak with Nora on navigating the complexities of the arts industry discussing their experiences with mental health, body positivity, and the importance of community support. The conversation delves into the challenges of being a performer, the role of advocacy in the arts, and the impact of negative feedback on self-esteem. Nora emphasizes the need for change within the industry and the importance of creating safe spaces for artists. They share the impact of their medical challenges on their career and the need for support and solidarity amongst their colleagues. Experiences with toxic education in the performing arts and the challenges of advocating for oneself in a high-pressure environment are touched on as well as the importance of kindness and growth in the industry, the privilege of being an educator and the responsibility that comes with it. Nora (they/them) graduated from The University of Michigan with a BFA in Musical Theatre and a minor in Gender, Race and Nation. They received Drama Desk, Drama League and Clive Barnes Award nominations for their Off-Broadway debut in SPAMILTON. Nora made their Broadway debut in JAGGED LITTLE PILL. They were most recently seen Off-Broadway playing Bustopher Jones in CATS: THE JELLICLE BALL. Nora will be performing all original music at the Perelman Center's Lobby Stage on November 2nd. Nora continues to cultivate a career focused on the intersection of performing and social justice. Love to Gregg Baker Management and their family.Follow / Resources / Mentions:IG: @noraschellmusicNora's Statement I PCOS I NAMI I Spamilton I Cats: “The Jellicle Ball” I Bipolar 2 Disorder I Borderline Personality Disorder I Drama Desk Awards I Drama League Awards I Clive Barnes Foundation I Bryan PerriSupport the showM.O.V.E. with Eileen + Amy is a Kaia Evolutions Podcast.New episodes air on Wednesdays when in season.To learn more about Eileen + Amy, be sure to follow them on IG at @ekielty + @amyreah and keep up to date on the podcast at @movewitheileenandamy. For more information about Kaia Evolutions, a culmination of Eileen's life's work and a love letter to her sister, Katie, who died by suicide in 2019 - visit https://www.kaiaevolutions.com/ or follow on IG at @kaia.evolutions If you want to share part of your dancer / movement artist journey with us, email us at movepod@kaiaevolutions.com*If you or anyone you know is in need of support, please call the National Suicide Prevention Lifeline at 800.273.8255 OR text 988. You are not alone.

On today's episode of Master Your Healthcare Career, we welcome Ethan Kannel, Director of Operations of the Perelman Center for Advanced Medicine at Penn Medicine. We welcome back Ethan, who completed an internship at CAHME in 2020.   After completing his MBA, Ethan was selected for a two-year Administrative Fellowship at Penn Medicine. He was hired on at Penn Medicine, as the Director of Operations for the Perelman Center for Advanced Medicine, a 900,000 square foot, $302 million dollar facility that sees approximately 820,000 patients per year.  On today's session, Dr. Stanowski and Ethan discuss the importance of fellowships and the valuable experiences they provide to students heading into the healthcare field.  Ethan discusses what helped him find a fellowship, what to do during the fellowship to secure a post-fellow role, and the qualities that he and Penn Medicine look for when interviewing potential candidates for a fellowship.  To read more about Healthcare Management Fellowships click here .

Leslie Koch offers a guided tour of the under-construction performing arts center, which will be the next building to open at the WTC site. She discusses the importance of arts and culture to Lower Manhattan and to a city that is just now beginning to recover from the pandemic. We witness the very first musical performance in the new building with violinist Gregory Harrington and cellist Eleanor Norton.  

Marc Bamuthi Joseph currently serves as the Vice President and Artistic Director of Social Impact at The Kennedy Center. He co-founded the Life is Living Festival for Youth Speaks, and created the installation “Black Joy in the Hour of Chaos” for Creative Time. His opera libretto, We Shall Not Be Moved, was named one of 2017’s “Best Classical Music Performances” by The New York Times, and his work /peh-LO-tah/ toured nationally. Future projects include commissions for the Perelman Center, Washington National Opera, and others, and a feature in HBO’s upcoming adaptation of “Between the World and Me” by Ta-Nehesi Coates. An inaugural recipient of the Guggenheim Social Practice initiative, Bamuthi also previously worked as the Chief of Program and Pedagogy at YBCA in San Francisco.

Work. Shouldn't. Suck. LIVE: The Morning(ish) Show with special guests Marc Bamuthi Joseph and Lisa Yancey. [Live show recorded: May 8, 2020.] LISA YANCEY is a strategist, social impact entrepreneur, community builder, and visionary who believes that people build legacies in a lifetime. Originally from Atlanta, Georgia, Lisa Yancey is the president Yancey Consulting (YC) and co-founder of SorsaMED and The We’s Match. With 18 years of practice, YC has served over 100 nonprofit organizations, grantmakers, and individuals. Advising across arts and culture, public space, and justice-based sectors, YC specializes in strategic organizational development, economic modeling, evaluation and assessments, board development, leadership coaching, and executive transition support. SorsaMED is a biotechnology company engineering cannabinoids infused with nutrient-enriched microalgae for therapeutic pain management, with a specific concern for sickle cell anemia sufferers, especially youth. The We’s Match is dedicated to the wealth, scale, and wellness of Black women entrepreneurs. We match these entrepreneurs with resources and capital for business growth and success. Lisa’s dedication to supporting equitable outcomes for systemically disenfranchised people is the seamless thread that binds these companies. Three essential philosophies drive Lisa’s work. One, we must disrupt patterns that either sustain or are complicit to inequities that challenge any person’s or group’s ability to be their full selves. Two, we will never accomplish sustainable goals looking solely in the short-term. She touts, “It is imperative to assess and set generational impact goals (20-25 years from now) that connect to present-day efforts.” The third is best captured in Lilla Watson’s declaration, “If you have come here to help me you are wasting your time, but if you are here because your liberation is bound with mine, then let us work together.” Lisa believes, “I am one of WE.” Lisa matriculated from Boston College Law School and Emory University. She is a former dancer and choreographer. She is also a member of the New York State Bar Association. Lisa currently lives in Mount Vernon, New York, and serves on the board of Fractured Atlas. MARC BAMUTHI JOSEPH is a 2017 TED Global Fellow, an inaugural recipient of the Guggenheim Social Practice initiative, and an honoree of the United States Artists Rockefeller Fellowship. He is also the winner of the 2011 Herb Alpert Award in Theatre, and an inaugural recipient of the Doris Duke Performing Artist Award. In pursuit of affirmations of black life in the public realm, he co-founded the Life is Living Festival for Youth Speaks, and created the installation “Black Joy in the Hour of Chaos” for Creative Time. Joseph’s opera libretto, We Shall Not Be Moved, was named one of 2017’s “Best Classical Music Performances” by The New York Times. His evening length work, /peh-LO-tah/, successfully toured across North America for three years, including at BAM’s Harvey Theater as a part of the 2017 Next Wave Festival. His piece, “The Just and the Blind” investigates the crisis of over-sentencing in the prison industrial complex, and premiered at a sold out performance at Carnegie Hall in March 2019. Bamuthi is currently at work on commissions for the Perelman Center, Yale University, and the Washington National Opera as well as a new collaboration with NYC Ballet Artistic Director Wendy Whelan. Formerly the Chief of Program and Pedagogy at YBCA in San Francisco, Bamuthi currently serves as the Vice President and Artistic Director of Social Impact at The Kennedy Center.

Dr Carolyn Lam: Welcome to circulation on the run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley: And I'm Greg Hundley, associate editor from the Pauley Heart Center at VCU health in Richmond, Virginia. Well Carolyn, our feature this week really examines long-term efficacy of drug eluting stents versus coronary artery bypass grafting in those patients with left main disease. Really looking at long-term extended follow up from the PRECOMBAT trial but before we get to that, how about we grab a cup of coffee and jump into some of the other articles in the issue? And I'll start off. My first article is a basic science paper looking at catecholamine sensitive and ventricular tachycardia in ARVC. And it comes from Dr Long-Sheng Song from the University of Iowa Carver College of Medicine. So, the study from Dr Song used protein mass spectrometry analyses and that identified integrin beta one is downregulated in those patients with arrhythmogenic right ventricular cardiomyopathy hearts without changes to calcium handling proteins as adult cardiomyocytes express only the beta-1 D isoform, they generated a cardiac specific beta-1 D knockout mouse model and perform functional imaging and biochemical analyses to determine the consequences from integrin beta-1 D loss of function in hearts in vivo and in vitro. Dr Carolyn Lam: Nice, very elegant design. So what were the results Greg? Dr Greg Hundley: Well Carolyn, the authors found that integrin beta- 1D deficiency and RyR2 serine 2030 hyper phosphorylation were detected by Western blotting in left ventricular tissues from patients with ARVC but not in patients with ischemic or hypertrophic cardiomyopathy. And in the mouse experiments, beta-1 D negative or knockout mice exhibited normal cardiac function and morphology, but presented with catacholamines sensitive polymorphic ventricular tachycardia consistent with increased RyR2 serine 2030 phosphorylation and apparent calcium handling in beta-1 D knockout cardiomyocytes. So Carolyn, in conclusion, the authors found their data suggest that integrin beta-1D deficiency represents a novel mechanism underlying the increased risk of ventricular arrhythmias in patients with ARVC. Dr Carolyn Lam: Okay. You told us about integrin beta-1 D and I'm going to tell you about apolipoprotein M. So Greg, what do you know about apolipoprotein M? Dr Greg Hundley: Well, Carolyn, at seven o'clock the morning, I seem to have forgotten a little bit about that. Can you remind me what apolipoprotein M is? Dr Carolyn Lam: Sure Greg, very happy to. So apolipoprotein M or apoM mediates the physical interaction between high density lipoprotein particles and sphingosine 1-phosphate and exerts an anti-inflammatory and cardio-protective effects in animal models. Now listen on, listen on. So authors, Dr Chirinos from Perelman Center for Advanced Medicine, University of Pennsylvania and Dr Javaheri from Washington University School of Medicine and co-authors hypothesized that reduced levels of apoM would be associated with worse outcomes in human heart failure. Specifically, they tested the hypothesis that reduced circulating apoM would be associated with the risk of death, a composite of death, ventricular assist, device implantation or heart transplantation and a composite of death, heart failure related hospitalization among adults with heart failure and rolled in a large multicenter Penn heart failure study. They did stratified analysis in patients with heart failure with reduced and preserved ejection fraction and even replicated these findings in two independent cohorts, the Washington University heart failure registry and a subset of the TOPCAT trial. What they found was that reduced apoM plasma protein levels indeed were associated with adverse outcomes in heart failure including both HFpF and HFrF. The relationship between reduced apoM and outcomes and heart failure was particularly pronounced when concentrations of its binding partner sphingosine 1-phosphate were also reduced. ApoM protein levels were associated with inflammation in human heart failure and thus the conclusion being that apoM represents a risk marker in human heart failure. Further studies are of course needed to assess whether it could be a therapeutic target as well. Dr Greg Hundley: Very good. Carolyn. So more information for the world of heart failure isn't it. I'm going to sort of switch over to coronary artery disease and talk about low attenuation non-calcified plaques that are sometimes appreciated on cardiac computed tomography scans. And in this study, Dr Michelle Williams from the University of Edinburg evaluated the results from the multi-center SCOT-HEART trial or the Scottish computed tomography of the heart. So Carolyn, the future risk of myocardial infarction is commonly assessed using cardiovascular risk scores, coronary artery calcium score or coronary artery stenosis severity and the authors assessed in 1,769 patients about 56% men and the average age 58 years and they followed them up for a median of 4.7 years and looked at whether noncalcified low attenuation plaque burden on coronary CT angiography might be a better predictor of the future risk of myocardial infarction. Dr Carolyn Lam: Interesting. So what did they find? Dr Greg Hundley: Well, low attenuation plaque burden was the strongest predictor of myocardial infarction irrespective of cardiovascular risk score, coronary artery calcium score or coronary artery area stenosis. And patients with low attenuation plaque burden greater than 4% were nearly five times more likely to have subsequent myocardial infarction and the hazard ratio was 4.65 with a confidence interval of two to more than 10 and a half. So in conclusion, Carolyn in patients presenting with stable chest pain, low attenuation plaque burden is the strongest predictor of fatal or nonfatal myocardial infarction and these findings may add to classical risk predictors of myocardial infarction. Dr Carolyn Lam: Wow. Important findings. Okay, let's go onto what else is in this week's journal issue. There's an online mind by Dr Jaffe. It's on the universal definition of myocardial infarction. It talks about both present and future considerations. There's an ECG challenge by Dr Arias and what's described as spontaneous wide QRS complex rhythm in a patient with wide QRS complex tachycardia. Dr Greg Hundley: Very good, Carolyn. Well, I've got two other articles. Another on my mind piece from Professor Peter Nagele from the University of Chicago Medicine and it discusses a simplified proposal to redefine acute MI versus acute myocardial injury. Looking at that troponin question. And then finally Dr Fabian Hoffman from the Heart Center and University of Cologne has a research letter on providing new data regarding the evolution of pulmonary hypertension during severe sustained hypoxia. Well Carolyn, how about we get onto that feature discussion looking at left main disease and whether we should place an intercoronary stent or undergo coronary artery bypass grafting. Dr Carolyn Lam: Important question. Let's go, Greg. Dr Greg Hundley: Welcome everyone to our feature discussion today that really pertains to interventional cardiology and we're very fortunate to have Duk-Woo Park from Asian Medical Center in Seoul, South Korea and our own associate editor, Dr Manos Brilakis from the Minneapolis Heart Institute. Well Duk-Woo, we'd like to get started with you and could you tell us a little bit about the background data and the hypothesis related to your research study? Dr Duk-Woo Park: Our research, it was the 10-year report of the PRECOMBAT trial. If I'm going to first introduce the background over the last half of a century bypass surgery, it was a mainstream, the number one choice of on protecting the main disease. Yeah. Did you know unprotected left main disease, the one were very high risk of coronary artery disease and owing two and the supply, the large burden of myocardium. But the last two decades, 20 years. Their remarkable evolution in PCI field including development adaption of a drug eluting stent and the adaption of intravascular ultrasound as well as experience of intervention or catalyst expertise. So on the basis of such evolution, many interventional cardiologists think about that, a PCI with a drug eluting stent. Will it be non-inferior to a standard type A surgery? Sometime for single region PCI could be very nice alternative option for unprotected left main disease that the reason why we're going to start quick on the trial. This trial already done 15 years ago at the time. We designed this PRECOMBAT trial on the basis of that background. Dr Greg Hundley: Very good. Well can you tell us a little bit about the study population of this trial and what was your study design? Dr Duk-Woo Park: This is a open library trial design and we at first time we evaluated the noble unprotected left main disease and the for considerable for clinical and ethic eligibility, initially assessed by intervention or cardiologists as you as a cardiac surgeon and the reason why we try to pick up the post treatment eligible population and then at the screening initial re-screen the nearly 1,400 patient and then finally 600 of patient who was our individuation one arm is drug eluting stent, first-generation ciphers 10 versus another arm is convention or a coronary artery bypass stent grafting. Dr Greg Hundley: What were you looking for your outcome measures and how long did you follow these patients? Dr Duk-Woo Park: Initially and the BDN two year follow and are published in England, the journal of medicine nearly eight years ago. And then we did five year follow-up at the publish the JAG in five years ago and the this time is a, we did complete that 10 year follow up all the render mutation population and the median follow-up duration is nearly more than 11 years and we complete 10 year follow-up and the key outcome was PCI is a comparable apart from surgery for treatment of left main disease. Dr Greg Hundley: And were there other outcomes that you were looking for? Dr Duk-Woo Park: We evaluated several important clinical outcomes. We primary end the point we select competent outcome compass of all cause of mortality by myocardial infarction, stroke, or ischemia-driven target vessel revascularization. Secondary outcome was each component of a primary outcome all-cause mortality as you raise the harder clinical and the point like compost outcome like this am I sure. So finally we did not any statistical difference with the regard to primary composite outcome as well as a hard clinical compost outcome as death or stroke. Finally, we did not detect all-cause mortality. One exception or difference was a target vascularization as well as a repeat rebase collateralization was a much higher after PCI than after bypass surgery. Dr Greg Hundley: So overall, in this more lengthy follow up of 10 years. The primary outcomes were similar between the two interventional arms, but there was a difference in target vessel revascularization. With that being more frequent after PCI as compared to bypass, were there any other subgroups that tended to have distinctions or discrepancies between your primary outcome? Dr Duk-Woo Park: As the sensitive to analysis, in circulation we supply the subgroup analysis or more, we did not find any differential treatment. IPEC according to subgroup in age group, diabetes and clean-cut presentation or in environmental coronary embolism shock versus application. We didn't find any interaction effect, just the except the extent of disease vessel, left or main. We the three best three digit bypass surgery was better than PCI. However we did not do any P value. Adjust them on. So interpretation is should it be cautious. Dr Greg Hundley: Well you know as an interventional cardiologist, what new information does this bring and how do you interpret the results of this study relative to other studies that have been published in the past? Dr Emmanouil Brilakis:  I think this is a very timely study, especially since about a year ago we did have the five-year outcomes from two other similar trials, the Excel file and the Nobel trial which say randomized patients with unprotected left main disease to either PCI or bypass. And actually those studies had some differences which are also relevant to the present study. So for example, Excel overall the outcomes were similar. There was a higher all-cause mortality in the PCI where normal had better outcomes in terms of death, MIT VR, but there was no difference in mortality. So I think the natural question that comes up from the studies was whether mortality is different with PCI versus coronary bypass and you know the PRECOMBAT, the 10 years. It's really suiting in that respect because it doesn't show any difference in the overall mortality. So I think this comes very timely and the answers a lot of questions. Of course there's limitations with the sample size and the number of patients treated, but I think although it's a very timely result. Dr Greg Hundley: Maybe I'll start first with you, Manos and then I'll circle back to you. Duk-Woo. Manos what do you see is the next important study to perform in this field? Dr Emmanouil Brilakis:  I think the natural question here is these outcomes which are similar but use first generation drug eluting stents, which we no longer use. He did use high proportion of five which is an excellent feature in, again congratulate Duk-Woo and the other co-investigators for doing such a high rate of follow-up. But we now know that the techniques, for example, for bifurcations, maybe the DK crush or double DK crush might be a better technique to do. So in my mind, the next question would be if who use the current, a much improved the drug eluting stent and state of the art bifurcation techniques. For example, DK crush where the double-kiss crush bifurcation would, the outcomes have been different and perhaps PCI will be similar, even better than bypass in long-term outcomes. So for me this next study will be state of the art techniques, state of the art materials and long-term for follow-up as in frequently. Dr Greg Hundley: Duk-Woo. How about from your perspective? Dr Duk-Woo Park: You know, a future perspective is a very difficult to expect. Our trial is the longest to follow-up trial. We have the nation are insurance support and we nearly a hundred percent pop picked up fighters status, but I think most of them interventional cardiologists as well as a cardiac surgeon. One true additional longest follow-up Excel and Noble trial. The reason why we didn't do additional random trial using additional second generation drug eluting stent. We already do exit trial approximately 2000 and noble trial and more than thousand patients we already do and the two trial a complete five-year follow and most of the trial is as well as the clinician want to extend the follow-up of Excel and Noble trial but I don't know how much that extended of a follow-up would be possible. Dr Duk-Woo Park: The next step as you know the intervention or cardiac surgeon still debate about the long-term mortality issue after release of exited five-year-old research and the data peak issue, European association cardiac thoracic group. We did draw the endorsement of a guideline so I think an additional stem we require the individual patient level data analysis involving, Excel, Nobel, Syntech and PRECOMBAT trial would be required to provide the more definite compelling evidence for mortality difference as well as the have the end point and including or so some end point to repeat revascularization. We do allow individual patient data analysis. That would be next. The short step, next the long step, we definitely require extended follow-up, Excel and Noble trial. Dr Greg Hundley: Very good. Well listeners, this has been another very informative feature discussion where we've compared PCI and coronary artery bypass grafting in those with left main disease. And now from this PRECOMBAT trial, 10 years of follow up showing very similar outcomes related to death, myocardial infarction and stroke in the two randomized arms. We want to thank Dr Duk-Woo Park and Dr Manos Brilakis for presenting this information and as we move forward, their insights as to next studies with newer technologies and different examinations of stents. More long-term follow-up from ongoing trials and then individualized patient assessments. Listeners, we hope you have a great week and hope everyone is staying safe in this COVID crisis. Take care. This program is copyright of the American Heart Association 2020.  

Join Madeline in CHOP’s “lab of the future” in the Leonard and Madlyn Abramson Pediatric Research Center. As Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and Chief Scientific Strategy Officer at CHOP, Dr. Davidson is developing innovative gene therapies to treat inherited brain disorders. Listen in as she talks to Madeline about everything from her earliest breakthrough moment to what it’s like to be a woman in a male-dominated field. You can learn more about supporting research and discovery at CHOP here. #ForBreakthroughs

Are you overwhelmed by over-the-counter product choices for psoriatic disease? Hear what to look for and practical tips for use from Veronica Richardson, a certified nurse practitioner with Penn Dermatology, Perelman Center for Advanced Medicine in Philadelphia. 

Suzan founded Tillotson Design Associates with twenty-three years of lighting design experience. She has won over one hundred lighting design awards for her work, including a 2018 International Dark Sky Association Lighting Design and Technology Award and the 2017 Lighting Designer of the Year at the Lighting Design Awards. Suzan Tillotson is one of the finest lighting designers in the world right now and I am honored to have met her already 9 years ago. Now I am fortunate to get to know and share the story behind her success, challenges, highlights and trends she observes in the lighting design industry that are needed or are about to happen. Please check out her amazing projects and references here: http://www.tillotsondesign.com/ Suzan has also been featured in numerous national and international publications. She is a former member of the IALD Board of Directors, a former IALD NY area Regional Coordinator, and was president of the IES Southwest Louisiana Section. She has also served as an awards judge for the New York IES Lumens and the IALD. Suzan has taught the New York IES Introductory Lighting Course, and numerous lighting design and rendering workshops. She has guest lectured on lighting design at Louisiana State University, New Jersey Institute of Technology, University of Arkansas, Cornell University, McGill University, and Dalhousie University. She also taught lighting to graduate-level architecture students at Princeton University. Suzan was the keynote speaker for the 2018 United States Lighting Magazine 40 Under 40 Awards and a presenter at the 2017 Dark Sky Association Annual Meeting and the 2017 Lightspace Conference in LA. Suzan graduated with a Bachelor of Interior Design; from the Louisiana State University School of Architecture where, in 2012, she gave the commencement speech and was the recipient of the 2012 Distinguished Alumni Award. Suzan has directed all phases of design for a wide variety of award-winning domestic and overseas interior and exterior lighting projects including the new Bloomberg European Headquarters and London Mithraeum in London, UK; the Dee and Charles Wyly Theater in Dallas, TX; the R/GA Offices; Lincoln Center North Plaza and South Campus; and One Vanderbilt Tower, the Perelman Center at WTC, and the New Museum of Contemporary Art; in New York, NY. You can also find the Light Lounge Podcast on Anchor, Spotify, Apple Podcast. In order to promote professional lighting design, please help spread the word, leave a great rating on Apple Podcast or say hi on Instagram thomas_mnich More info: hhttp://www.thomasmnich.com/podcast

Originally recorded at the 4th annual Immuno-Oncology 360° 2018 event, Dr Corey Langer, Director, Thoracic Oncology and Professor of Medicine for the Perelman Center for Advanced Medicine at the University of Pennsylvania, discusses data on Keytruda in combination with chemotherapy in non-small cell lung cancer. This year, the University of Pennsylvania will be represented by Dr Marco Ruella, Assistant Professor and Scientific Director Lymphoma Program, Division of Hematology and Oncology, Department of Medicine and Center for Cellular Immunotherapies. Dr Ruella will be discussing the next steps for CAR-T therapy for cancer on day three during the Next Generation Cell Therapy Plenary To join in on the discussion at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY!

Today's First Thing podcast touches on today's top stories: OSF’s Bill Rauch to take helm of Perelman Center in New York. No charges will be filed in Rogue River girl’s death. Third possible suspect sought in Central Point robbery. Read full versions of these stories at www.mailtribune.com. Listen to all Mail Tribune podcasts at www.mailtribune.com/podcasts.

The University of Pennsylvania had tremendous results with a recent clinical trial using a CAR T cell treatment targeting CD19 for a myeloma patient. The results were so impressive that some wonder if they have been able to eliminate the myeloma stem cell clone for one patient who had relapsed 9 therapies and had a high-risk genetic feature. Learn more about this success and where UPENN is going next using CAR therapy with Dr. Adam Cohen, MD, Director of Myeloma Immunotherapy at the Perelman Center for Advanced Medicine at UPENN. Thanks to our episode sponsor, Amgen.